Skip to main content

Table 2 Univariate and multivariate analyses in patients treated with chemotherapy

From: High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia

Variables

EFS

OS

HR (95% CI)

P-value

HR (95% CI)

P-value

Univariate analyses

 MiR-363 (high vs. low)

2.224 (1.369–3.612)

0.001

2.389 (1.468–3.887)

0.000

 WBC (≥ 20 vs. < 20 × 109/L)

1.015 (0.633–1.627)

0.952

0.980 (0.611–1.571)

0.932

 FLT3–ITD (positive vs. negative)

1.095 (0.587–2.040)

0.776

1.049 (0.563–1.956)

0.880

 NPM1 (mutated vs. wild)

1.050 (0.633–1.741)

0.850

0.965 (0.582–1.599)

0.890

 DNMT3A (mutated vs. wild)

1.301 (0.774–2.185)

0.320

1.299 (0.775–2.179)

0.321

 RUNX1 (mutated vs. wild)

1.502 (0.717–3.147)

0.281

1.591 (0.759–3.335)

0.219

 TP53 (mutated vs. wild)

3.011 (1.539–5.892)

0.001

2.898 (1.487–5.649)

0.002

 TET2 (mutated vs. wild)

0.778 (0.372–1.625)

0.504

0.686 (0.328–1.434)

0.316

 MLL–PTD (mutated vs. wild)

0.891 (0.324–2.445)

0.822

0.945 (0.344–2.596)

0.913

 IDH1/IDH2 (mutated vs. wild)

0.973 (0.271–1.273)

0.926

0.988 (0.550–1.777)

0.969

 NRAS/KRAS (mutated vs. wild)

1.214 (0.637–2.314)

0.556

1.228 (0.644–2.340)

0.532

Multivariate analyses

 MiR-363 (high vs. low)

2.362 (1.346–4.145)

0.003

2.683 (1.507–4.779)

0.001

 WBC (≥ 20 vs. < 20 × 109/L)

1.806 (1.036–3.151)

0.037

1.861 (1.056–3.280)

0.032

 RUNX1 (mutated vs. wild)

1.706 (0.797–3.654)

0.169

1.819 (0.850–3.892)

0.123

 TP53 (mutated vs. wild)

2.786 (1.312–5.915)

0.008

2.566 (1.221–5.395)

0.013

  1. EFS event-free survival, OS overall survival, WBC white blood cell